Literature DB >> 2198134

Obstructive sleep apnea treated by independently adjusted inspiratory and expiratory positive airway pressures via nasal mask. Physiologic and clinical implications.

M H Sanders1, N Kern.   

Abstract

Treatment of obstructive sleep apnea with nasal continuous positive airway pressure mandates simultaneous increases of both inspiratory and expiratory positive airway pressures to eliminate apneas as well as nonapneic oxyhemoglobin desaturation events. We hypothesized that the forces acting to collapse the upper airway during inspiration and expiration are of different magnitudes and that obstructive sleep-disordered breathing events (including apneas, hypopneas and nonapneic desaturation events) could be eliminated at lower levels of EPAP than IPAP. To test these hypotheses, a device was built that allows the independent adjustment of EPAP and IPAP (nasal BiPAP). Our data support the hypotheses that expiratory phase events are important in the pathogenesis of OSA and that there are differences in the magnitudes of the forces destabilizing the upper airway during inspiration and expiration. Finally, applying these concepts, we have shown that by using a device that permits independent adjustment of EPAP and IPAP, obstructive sleep-disordered breathing can be eliminated at lower levels of expiratory airway pressure compared with conventional nasal CPAP therapy. This may reduce the adverse effects associated with nasal CPAP therapy and improve long-term therapeutic compliance.

Entities:  

Mesh:

Year:  1990        PMID: 2198134     DOI: 10.1378/chest.98.2.317

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  40 in total

Review 1.  Treatment options for sleep apnoea.

Authors:  R R Grunstein; J Hedner; L Grote
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Effect of reduced expiratory pressure on pharyngeal size during nasal positive airway pressure in patients with sleep apnoea: evaluation by continuous computed tomography.

Authors:  M Gugger; P Vock
Journal:  Thorax       Date:  1992-10       Impact factor: 9.139

Review 3.  New developments in the use of positive airway pressure for obstructive sleep apnea.

Authors:  Lucas M Donovan; Schafer Boeder; Atul Malhotra; Sanjay R Patel
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

Review 4.  Sleep.7: positive airway pressure therapy for obstructive sleep apnoea/hypopnoea syndrome.

Authors:  P Gordon; M H Sanders
Journal:  Thorax       Date:  2005-01       Impact factor: 9.139

5.  Compliance with and effectiveness of adaptive servoventilation versus continuous positive airway pressure in the treatment of Cheyne-Stokes respiration in heart failure over a six month period.

Authors:  C Philippe; M Stoïca-Herman; X Drouot; B Raffestin; P Escourrou; L Hittinger; P-L Michel; S Rouault; M-P d'Ortho
Journal:  Heart       Date:  2005-06-17       Impact factor: 5.994

Review 6.  Positive pressure therapy: a perspective on evidence-based outcomes and methods of application.

Authors:  Mark H Sanders; Josep M Montserrat; Ramon Farré; Rachel J Givelber
Journal:  Proc Am Thorac Soc       Date:  2008-02-15

7.  Noninvasive positive pressure ventilation in infants with upper airway obstruction: comparison of continuous and bilevel positive pressure.

Authors:  Sandrine Essouri; Frédéric Nicot; Annick Clément; Erea-Noel Garabedian; Gilles Roger; Frédéric Lofaso; Brigitte Fauroux
Journal:  Intensive Care Med       Date:  2005-02-15       Impact factor: 17.440

8.  Opioid-associated central sleep apnea: a case series.

Authors:  M A Alattar; S M Scharf
Journal:  Sleep Breath       Date:  2008-09-20       Impact factor: 2.816

9.  Progress toward a clearer understanding of the role of bilevel positive airway pressure therapy for obstructive sleep apnea.

Authors:  Charles W Atwood
Journal:  J Clin Sleep Med       Date:  2013-04-15       Impact factor: 4.062

Review 10.  Pathophysiology of sleep apnea.

Authors:  Jerome A Dempsey; Sigrid C Veasey; Barbara J Morgan; Christopher P O'Donnell
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.